





RETeval-DR™ Electroretinograph

In just **THREE MINUTES**,
you can screen for
diabetic retinopathy
**WHEREVER PATIENTS
RECEIVE CARE.**



Welch Allyn **VISION FOR ALL**



Diabetic retinopathy is the **leading cause of blindness** among working-age adults. However, with early detection and treatment, most cases can be prevented.



TRAGICALLY, DOCUMENTED COMPLIANCE WITH VISION-SAVING ANNUAL EXAMS IS OFTEN LESS THAN 50%.



COMFORTABLE NON-MYDRIATIC SCREENING IN JUST THREE MINUTES.



WITH EARLY DETECTION, 95% OF VISION LOSS CASES CAN BE PREVENTED.

Objectively Screen for

Vision-Threatening

Diabetic Retinopathy

- Mild Non-Proliferative DR
- Moderate Non-Proliferative DR
- Severe Non-Proliferative DR
- Proliferative DR
- Clinically Significant Macular Edema

Absent CSME, mild to moderate NPDR is typically not treated with laser or anti-VEGF therapy.*


* American Academy of Ophthalmology Diabetic Retinopathy Preferred Practice Guidelines 2014, Table-6.

RETeval-DR is designed for healthcare providers who want to
RETeval-DR effectively screens for vision-threatening diabetic retinopathy



NON-MYDRIATIC FOR COMFORT


Dilated retinal examinations can be uncomfortable, time-consuming and sometimes costly. Only RETeval-DR uses a built-in pupilometer to adjust flash intensity so dilation is not necessary, to enable a quick and comfortable exam and enhanced patient satisfaction.



QUICKLY SCREEN FOR VTDR

Screen for vision-threatening diabetic retinopathy (VTDR) in just three minutes **WHEREVER PATIENTS WITH DIABETES RECEIVE THEIR CARE.** No advanced clinical training is required to perform the test or read the results. RETeval-DR offers significant time savings for both patients and physicians—especially when compared with having to make a separate appointment.

RETeval-DR can be used wherever patients receive care.




PRIMARY CARE



EYE CARE




PHARMACY



OUTREACH

to improve management of their patients with diabetes.
pathy with a 99.2% negative predictive value.¹



LOWER SCREENING COSTS

Compared to dilated eye exams and teleretinal imaging services that require costly fundus cameras, RETeval-DR offers healthcare systems and providers an effective way to screen for vision-threatening diabetic retinopathy at a lower cost.



EFFICIENT FOR EYE CARE

Fast, non-mydratic RETeval-DR electroretinograph technology augments traditional diabetic retinopathy screening techniques. It enables busy eye care specialists to more efficiently screen patients with diabetes, but without diagnosed retinopathy, to help enhance patient throughput and satisfaction.

How Welch Allyn RETeval-DR Serves You Better

TRUSTED GLOBAL BRAND

For 100 years, Welch Allyn has brought a unique perspective to developing diagnostic solutions by combining pragmatic knowledge with a visionary spirit of innovation. Whether you have one office or are managing a national program, Welch Allyn has the talent and resources to scale and match your requirements.

UNIQUE ELECTRORETINOGRAPH (ERG) TECHNOLOGY MADE SIMPLE

ERG is an instrument for measuring the electrical response of the retina to light stimulation—a fundus image is not required. **Similar to an ECG**, electrical activity of the retina is magnified and recorded as waves with patented non-invasive RETeval-DR Sensor Strips that comfortably rest below each eye. Signals from a diseased retina are reduced in size and slower than normal.



HIGH ACCURACY AND LOW TECHNICAL FAILURE RATE

Validated¹ using gold standard ETDRS 7-standard field photography, RETeval-DR's performance compares favorably to one point-of-care digital retinal imaging system (Joslin Vision Network, Boston, MA) for the detection of severe NPDR or worse, with better sensitivity (87% vs. 85%), and lower specificity (78% vs. 100%) than the digital retinal system. The RETeval device's technical failure rate (0.9%) was much better than that reported for the digital retinal imaging system (35%)², and RETeval is largely unaffected by cataracts and generates results even with small pupils (down to 1.3 mm).

HANDHELD AND BATTERY POWERED

The handheld and completely portable RETeval-DR enables screening to take place wherever patients with diabetes receive their care—whether in primary care, a specialist setting, a pharmacy, or even a remote healthcare screening event.

IMMEDIATE TEST RESULTS AND REPORT

A complete ERG report based upon the retinal evaluation is available immediately on the screen and as a PDF file—no data transfer over the Internet is required.

NO INSTALLATION AND MINIMAL TRAINING REQUIRED

RETeval-DR does not require complicated installation or dedicated floor space and arrives ready to use. Device prompts on the display screen guide the user through a three-minute exam that delivers an objective result. No advanced clinical training is required to perform the test or read the results.

¹Multi-center, cross-sectional, 500 subject, clinical calibration / validation study of RETeval device in patients with diabetic retinopathy, 2014. Principal Investigator: Stephen R. Fransen, MD, Chief Medical Officer, Inveon Corporation.

²Ahmed J, Ward TP, Bursell SE, Aiello LM, Cavallerano JD, Vigersky RA: The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes care 2006;29:2205-2209

ORDERING INFORMATION

RETeval-DR is currently intended for export, and is not sold or offered for sale in the U.S.A.

RETeval-001 Welch Allyn RETeval-DR Electroretinograph including Disposable Sensor Strips (100 Pair), Charging Dock, and USB Cable; Lithium-Ion Battery (#RETeval-ACC-02); 100-240 V, 50-60 Hz; IEC Plug Types A, G, E/F, and I; Multiple Languages

RETeval-SS-50 Disposable Sensor Strips for Welch Allyn RETeval-DR Electroretinograph; (50 Pair)

Welch Allyn VISION FOR ALL

The Welch Allyn Vision For All initiative is focused on delivering frontline solutions that will help to reduce or eliminate some of the leading causes of preventable blindness and vision-threatening conditions. This effort is dedicated to improving patient access to vision-saving technology by providing simple, affordable, advanced screening solutions to primary care physicians and eye care specialists.

For more information about Welch Allyn VISION FOR ALL or RETeval-DR, please contact your Welch Allyn representative or visit www.RETeval-DR.

Welch Allyn, Inc.
4341 State Street Road
Skaneateles Falls, NY 13153 USA
(p) 800.535.6663 (f) 315.685.3361

WWW.WELCHALLYN.COM

WelchAllyn®